Aberrant Gene Expression Prostate Carcinoma
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Prostate Cancer, Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 3/1/2019 |
| Start Date: | April 1995 |
| End Date: | April 2025 |
Identification of Aberant Gene Expression in Human Prostatic Carcinoma
The goal of the study is to gain a better understanding of the molecular changes responsible
for causing prostate cancer and that examination of tissue and blood samples will help in the
development of improved screening and therapeutic approaches.
for causing prostate cancer and that examination of tissue and blood samples will help in the
development of improved screening and therapeutic approaches.
The goal of this study is to identify novel genetic elements that are aberantly expressed
throughout prostatic neoplastic progression. The approaches proposed exploit the known
familial arm of prostatic cancer, using established molecular genetic approaches, and extend
these studies to sporadic prostatic cancer using a novel technique of differential display.
Application of the latter technique to colon cancer in the American population establishes
this tumor type as a high priority for scientific investigation and this study is part of an
initiative to address this problem. Presently the studies in the field of prostate are
under-represented. The collection of tissue samples from patients diagnosed with prostate
cancer. Patients will also provide a blood sample at the time of their surgery and
potentially post-op from 6 mos to 5 years. Samples will also be obtained from patients who's
biopsy turns out to be non-prostate cancer. These samples will be obtained shortly following
the biopsy out to 6 months after the biopsy.
throughout prostatic neoplastic progression. The approaches proposed exploit the known
familial arm of prostatic cancer, using established molecular genetic approaches, and extend
these studies to sporadic prostatic cancer using a novel technique of differential display.
Application of the latter technique to colon cancer in the American population establishes
this tumor type as a high priority for scientific investigation and this study is part of an
initiative to address this problem. Presently the studies in the field of prostate are
under-represented. The collection of tissue samples from patients diagnosed with prostate
cancer. Patients will also provide a blood sample at the time of their surgery and
potentially post-op from 6 mos to 5 years. Samples will also be obtained from patients who's
biopsy turns out to be non-prostate cancer. These samples will be obtained shortly following
the biopsy out to 6 months after the biopsy.
Inclusion Criteria:
- Diagnosed prostate cancer undergoing prostatectomy
- Suspicion of prostate cancer undergoing biopsy - negative biopsy
- Health volunteer (control group) - blood sample for PSA
Exclusion Criteria:
- Patients not fitting the inclusion criteria
We found this trial at
1
site
Lahey Clinic When Frank Lahey, MD, founded a group practice in 1923, his vision was...
Click here to add this to my saved trials
